Pharma Business - May 5, 2025
Cantargia announces second target indication for CAN10
Cantargia has announced the selection of a subgroup of atopic dermatitis (AD) patients, not responding to first line dupilumab treatment, as its second target indication for CAN10.
Pharma Business - April 29, 2025
Purpose Pharma receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Attrogy (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Agreement - April 14, 2025
OncoZenge in agreement for BupiZenge in the GCC Region
OncoZenge and Avernus Pharma General Trading, a pharma marketing company from the UAE, have signed an exclusive agreement to license BupiZenge for commercialization and distribution in the Gulf Cooperation Council (GCC) region.
Acquisition - April 10, 2025
EQT to sell Karo Healthcare to KKR
EQT and KKR has announced that EQT VIII fund has agreed to sell Karo Healthcare to KKR.
Collaboration - April 8, 2025
Circio initiate collaboration with Entos Pharmaceuticals
Circio Holding (former Targovax) and Entos Pharmaceuticals have announced the initiation of a research collaboration.
Biotech Business - April 1, 2025
FDA removes clinical hold of Oncopeptides’ OPD5
Oncopeptides has announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
